Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Eyenovia’s Redwood City Facility Clears FDA Inspection
Eyenovia announced the successful completion of the FDA inspection for its facility in Redwood City, California, marking a significant milestone in the company’s manufacturing capabilities. This achievement signals the green light for the facility to engage in final assembly, packaging,…
FDA Gives Green Light to OK-101 Trial for NCP Treatment
Okyo Pharma’s first investigational new drug (IND) application for OK-101 has been cleared by the U.S. Food and Drug Administration (FDA), marking a pivotal moment in the development of potential therapies for neuropathic corneal pain. Initially proposed as an open-label…
Low-Dose Atropine Eye Drops & Myopia Progression
According to the National Eye Institute (NEI), a trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the NEI revealed that the use of low-dose atropine eye drops (concentration 0.01%) did not demonstrate superiority over a…
Glaukos Secures FDA Approval for iDose TR
Glaukos has received FDA approval for iDose TR (travoprost intracameral implant 75 mcg), a groundbreaking prostaglandin analog intracameral implant designed to reduce intraocular pressure (IOP) in individuals with ocular hypertension or open-angle glaucoma. The iDose TR procedure, sanctioned for a…
FDA Calls for Study on Aldeyra’s Reproxalap in DED
Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…
Reviving Hope for Amblyopia: Late-Stage Treatment
In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…
UCL-Moorfields Eye Hospital Secures £5M for Research Center
The Sir Jules Thorn Charitable Trust has allocated £5 million towards the establishment of a research center within Oriel, the collaborative initiative between UCL and Moorfields Eye Hospital aimed at advancing eye health. Partnering with Moorfields Eye Charity and Moorfields…
Negative Effect of Atropine Drops After Glaucoma Surgery
According to a report by an international team of researchers, atropine instillation after trabeculectomy should be discouraged since it causes greater and longer lasting reduction in visual quality.1 The study’s lead author is Panagiotis Laspas, MD, of the Department of…
Perfluorohexyloctane Drops Help Alleviate Dry Eye
According to recent research, perfluorohexyloctane eye drops (SHR8058) demonstrated significant improvement in both the signs and symptoms of dry eye disease (DED) linked to meibomian gland dysfunction (MGD) with rapid effectiveness in Chinese patients. The findings showed that the perfluorohexyloctane…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…